Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Datamonitor
|
$50.00
|
|
Provider: GlobalData
|
$75.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Grindeks AS Issues FY 2011 Revenue Guidance above I/B/E/S Estimates-SeeNews Nordic
SeeNews Nordic reported that Grindeks AS expects to book a revenue of LVL 70 million (USD 131.3 million / EUR 100 million) for fiscal year 2011. According to I/B/E/S Estimates, the analyst are on average expecting the Company to report revenue for fiscal year 2011 of LVL 69.19 million.
Latest Developments for Grindeks AS
- Grindeks AS Appoints Mr. Juris Bundulis as New Chairman of Management Board
- Grindeks AS Appoints Mr. Juris Bundulis as New Chairman of Management Board
- Grindeks AS Approves Mr. Juris Bundulis as Candidate for New Chairman of Management Board
- Grindeks AS Announces Resignation of Mr. Janis Romanovskis from Chairman of Management Board
Latest Key Developments in Pharmaceuticals - Diversified
- ImmunoCellular Therapeutics Ltd Announces Positive Phase I results For Cancer Vaccine Candidate
- Chelsea Therapeutics International Ltd. Reports Results Of Phase II Trial Of CH-4051 In Rheumatoid Arthritis
- PhotoCure ASA Announces Positive Results of Phase 2B Study Evaluating Visonac in Acne
- Teva Pharmaceutical Industries Ltd Begins Trading on New York Stock Exchange
- Share this
- Link this
- Digg this
Follow Reuters